Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in active ankylosing spondylitis
NCT03178487Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of upadacitinib in ankylosing spondylitis (AS), sponsored by AbbVie Inc.. Started Oct 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03178487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178487.